

Hypomethylation in *FASTKD1* detected in the association between *in utero* tobacco exposure and conduct problem in a New Zealand longitudinal study

Alexandra J. Noble¹, John F. Pearson², Joseph M. Boden³, L. John Horwood³,
Martin A. Kennedy², Amy J. Osborne¹

¹ School of Biological Sciences, University of Canterbury, Christchurch, New Zealand

² Department of Pathology and Biomedical Science, University of Otago,
Christchurch, New Zealand

³ Department of Psychological Medicine, University of Otago, Christchurch, New
Zealand

Alexandra.noble@pg.canterbury.ac.nz

33

34 Abstract

35 Despite the known adverse effects of *in utero* tobacco exposure on offspring health,
 36 maternal tobacco use during pregnancy remains prevalent and is a major driver of
 37 health inequalities. One such health inequality is the development of conduct
 38 problem (CP) in exposed offspring which may be mediated by methylation changes
 39 that persist into adulthood. Here we apply a genome-wide approach to probe the
 40 association between maternal tobacco use during pregnancy and CP outcomes in
 41 exposed offspring. We examined maternal tobacco use during pregnancy (*in utero*
 42 exposure) in the Christchurch Health and Development Study, a longitudinal birth
 43 cohort studied for over 40 years. We then evaluated the interaction between
 44 methylation effects of *in utero* exposure and CP score. When modelling this
 45 interaction between *in utero* exposure and CP score we detected nominal DNA
 46 methylation differences, at *FASTKD1* which has roles in early development. Our
 47 observations are consistent with DNA methylation mediating the development of CP
 48 following *in utero* tobacco exposure. In addition, we detected nominal significance in
 49 *FRMDA4* and *MYO1G* between individuals exposed to tobacco *in utero* and those
 50 that were unexposed, however these did not reach significance after adjustment for
 51 multiple testing. However due to limited power in our analysis, further studies are
 52 needed to investigate the interaction between *in utero* tobacco exposure and high
 53 CP health outcomes.

54

55

56

57

58

59

60

61

62

63

64

65

66

67 Introduction

68

69 The use of tobacco during pregnancy is one of the leading causes of perinatal
70 compromise for developing offspring, and one of the most preventable [1]. For
71 example, low birth weight [2], congenital heart anomalies [3], asthma/respiratory
72 illness [4, 5], and sudden infant death syndrome (SIDS) [6] are all associated with
73 maternal tobacco use during pregnancy, the rate of which remains relatively high in
74 New Zealand (18.4% [7]), despite declining tobacco use rates overall [8].

75

76 While immediate perinatal compromise in infants due to maternal smoking is well
77 documented, the long-term effects into later childhood, adolescence and adulthood
78 are not understood. Maternal tobacco use in pregnancy has been associated with
79 later risks of mental health and related adjustment problems in childhood and
80 adolescence [9, 10]. Further, there is also evidence that maternal smoking during
81 pregnancy is associated with increased risks of conduct disorders and antisocial
82 behaviours in offspring [11] [12-14]. This association is not explained by postnatal
83 environment [15]. Further associations have been identified between maternal
84 tobacco use during pregnancy and the increased risk of the development of
85 attention-deficit hyperactivity disorder (ADHD) [16]. Also affected are offspring
86 neurodevelopment and behaviour, suggesting that poor behavioural adjustment
87 (often termed 'conduct problems', CP) can be considered a consequence of
88 maternal smoking during pregnancy [11]. While these traits can be linked to other
89 societal risk factors such as low socioeconomic status and early-life adversity [17],
90 their association with maternal tobacco use during pregnancy is intriguing. Tobacco
91 smoking is a strong modifier of DNA methylation [18-20]. We propose that tobacco
92 use during pregnancy could act on CP risk from *in utero* exposure on DNA
93 methylation. Understanding this association is crucial for furthering the paradigm of
94 the developmental origins of human health and disease (DOHaD) [21].

95 Overall there is a better understanding of the impact of *in utero* tobacco exposure on
96 DNA methylation and only limited preliminary work has been carried out on the
97 interaction between *in utero* tobacco exposure and the onset of CP [22]. Recent

research has demonstrated links between prenatal tobacco exposure and specific DNA methylation patterns of newborn offspring [23-26]. Importantly, tobacco-induced DNA methylation changes can persist into adolescence [27] [26, 28]. Further, meta-analyses of multiple CpG sites in the gene *GFI1* (Growth Factor Independent one transcriptional repressor) were found to be differentially methylated in adult offspring in response to being exposed to tobacco *in utero* [29]. In contrast, the role of DNA methylation in the association between *in utero* tobacco exposure and CP is less clear. Preliminary work by Sengupta et al. [22] found three loci with modest DNA methylation changes in response to maternal tobacco use during pregnancy and CP phenotypes, but the etiology of this link has not been fully explored. One potential mechanism is that differential DNA methylation induced during the *in utero* period is influencing the development of CP in childhood.

Here we hypothesise that given maternal tobacco use during pregnancy has been previously linked to offspring CP during early childhood and adolescence, and that maternal tobacco use during pregnancy can affect DNA methylation of offspring through to adolescence and adulthood, that DNA methylation is altered at genes that have biological relevance for CP phenotypes, in the whole blood of adults who were exposed to tobacco *in utero*. To test this hypothesis, we used the Illumina EPIC array to interrogate differential methylation in the DNA of participants from the Christchurch Health and Development Study (CHDS) whose mothers consumed tobacco during pregnancy.

Methods

A cohort of 109 participants from the CHDS (N= 1265 in total) gave blood samples at about age 28 which were used for Illumina EPIC array analysis (Table 1). CHDS participants were chosen based on their *in utero* tobacco exposure status, their adult smoking status, and their CP scores. The *in utero* tobacco exposure was defined as 10+ cigarettes per day throughout pregnancy. A total of 49 individuals fitted this description. Within this group, 23 of the participants were also adult smokers. A total number of 60 individuals were used for the non-exposed control group. Eight of these participants were adult smokers. Furthermore, in both the exposed and non-exposed groups there were individuals who were selected with either a 'high' or 'low'

score on a measure of childhood CP at age 7-9 years. Severity of childhood CP was assessed using an instrument that combined selected items from the Rutter and Conners child behaviour checklists [30-33] as completed by parents and teachers at annual intervals from 7-9 years. Parental and teacher reports were summed and averaged over the three years [34] to derive a robust scale measure of the extent to which the child exhibited conduct disorder/oppositional behaviours (mean (SD)= 50.1 (7.9), range 41-97). For the purposes of this report a 'high' score was defined as falling into the top quartile of the score distribution (scores > 53) and a 'low' score was defined as < 46.

All samples taken were whole blood and collected at approximately 28 years old, and DNA extractions were conducted using the Kingfisher Flex System (Thermo Scientific, Waltham, MA USA), as per the published protocols. DNA was quantified via NanoDrop™ (Thermo Scientific, Waltham, MA USA) and standardised to 100ng/μl. Equimolar amounts were shipped to the Australian Genomics Research Facility (AGRF, Melbourne, VIC, Australia) for processing via the Infinium® Methylation EPIC BeadChip (Illumina, San Diego, CA USA). The arrays were carried out in groups over three batches. One in 2016, one in 2017 and another in 2020. Analysis was carried out in R statistical software (Version 3.5.2). Quality control checks were performed on the raw data, firstly sex chromosomes and a total of 90 failed probes (detection P value of < 0.01 in at least 50% of samples) were excluded from the analysis. CpG sites known to be problematic due to adjacent single nucleotide variants or which did not map to a location in the genome were also excluded [35]. This left a total of 699,916 CpG sites for further analysis. Pre-processing was performed using Noob [36]. Normalisation was then visually inspected for performance using beta density distribution plots and Multi-dimensional scaling of the 5,000 most variable CpG sites. Hierarchical regression was used to investigate the best linear model to be fitted to the methylated/unmethylated or M ratios. The two following models were picked as the most robust equations to assess for differential DNA methylation for our data set.

In utero exposed only (model 1)

$$Y = \text{In utero exposed} + \text{year array was sampled (3)} + \text{principal components (4)} \\ + \text{adult smoking status} + \text{sex} + \text{social economic status (3)}$$

161 *In utero* exposed with the interaction of CP (model 2)

$$Y = \textit{In utero exposed} + \textit{CP} + \textit{year array was sampled} (3) \\ + \textit{principal components} (4) + \textit{adult smoking status} + \textit{sex} \\ + \textit{social economic status} (3) + \textit{in utero exposed: CP}$$

162

163 Analysis corrected for the following variables: i) year array was sampled (3 levels),
164 and; ii) population stratification (four principal components from 5000 most variable
165 SNPs [37]), adult tobacco status (bivariate), sex (bivariate), socioeconomic status
166 (three levels). Q-Q plots of the residuals were also used to generate lambda values
167 to assess for over-inflation. Linear regression models were used to generate the top
168 tables of differentially methylated CpG sites and were corrected for multiple testing
169 using the Benjamini-Hochberg method (BH). Differentially methylated CpG sites that
170 were intergenic were matched to the nearest neighbouring genes in Hg19 using the
171 R package GenomicRanges [38]. The package ggplot (Version 3.3.2) was used to
172 construct all dotplot graphs [39], with the log transformed normalised methylated and
173 unmethylated values plotted.

174

175

176

177

178

179

180

181

182

183

184

185

186

187 Results

188

189 Data analysis

190

191 Both the *in utero* exposed only (model 1), and the *in utero* exposed with the
192 interaction of CP (model 2) were assessed for genomic inflation via Q-Q plots
193 (Supplementary Figure 1A and B). No significant indication of inflation was observed
194 for either of the two models: *in utero* exposed only with $\lambda = 0.97$ (Supplementary
195 Figure 1A) and *in utero* exposed with the interaction of CP with $\lambda = 1.03$
196 (Supplementary Figure 1B).

197

198 Methylation differences from *in utero* exposed only individuals compared to non-
199 exposed controls (model 1)

200

201 Firstly, differences in DNA methylation in response to *in utero* exposure were
202 assessed, while adjusting for year array was sampled, four principal components,
203 adult tobacco smoking status, sex, and socioeconomic status. Results of this
204 analysis identified nominally significant differential DNA methylation between
205 individuals exposed to tobacco *in utero* compared to the non-exposed control group.
206 A total of 653 CpG sites had a P value less than 0.001, of these 222 were
207 hypomethylated and the rest (431) were hypermethylated.

208 Top tables of the most significant CpG sites were then constructed; the top 30 CpG
209 sites are displayed in Table 2. Several nominally significant CpG sites were
210 observed, although none were significant after adjustment for multiple testing. The
211 top five differentially methylated sites resided in four genes: two sites in *FRMD4A*
212 (5.1% and 4.6% differentially methylated), and one each in *MYOG1* (7.4% differential
213 methylation), *WIPF3* (3.1% differential methylation) and *RTN1* (3.1% differential
214 methylation). At all five of these CpG sites, differences decreased, indicating
215 hypomethylation in response to *in utero* tobacco exposure. This same trend is
216 observed in the other remaining top CpG sites, as 28/30 were hypomethylated but

not significant in the exposed group. This is further illustrated by scatter plots of the top four most significant CpG sites in Figure 1.

Methylation differences between *in utero* exposed with the interaction of conduct problems (model 2)

To investigate genome-wide differential methylation specific to the interaction between *in utero* tobacco exposure and CP score, we determined differential methylation between i) individuals with high CP vs. low CP scores who were exposed to tobacco *in utero*, and; ii) individuals with high or low CP scores who were not exposed to tobacco *in utero*). Dividing the data in this way allowed us to specifically ask whether exposure to tobacco *in utero* may be associated with a high CP score as a result of an alteration to DNA methylation.

Top tables of the most significantly differentially methylated CpG sites were constructed (model 2), with the top 30 CpG sites displayed in Table 3. No CpG sites were found to be significant after adjustment for multiple testing. Within the top 30 CpG sites, an even split was seen between hypo and hypermethylation. The magnitude of the differential methylation in the *in utero* exposed low vs. high CP, and the non-exposed low vs. high CP under the interaction model are all less than 1.2%. The top four most differentially methylated sites under this interaction are plotted in Figure 2 (CpG site cg12163448 in *FASTKD1*, cg01210554 with no known associated gene, cg13339919 in *SLC10A7* and cg21516989 in *LPIN1* on individual plots). Scatter plots, overlaid with a box, are fitted to the four subcategories for each CpG site: i) non- exposed low CP; ii) non-exposed high CP; iii) *in utero* exposed low CP, and; iv) *in utero* exposed high CP. Each of the four subcategories here has a range of methylation values for the individuals within the group.

Discussion

The effect of *in utero* tobacco exposure has been widely found to induce differential DNA methylation marks in the genomes of exposed offspring, however much of what we know comes from studies involving infants and young children. Here, we investigated the effect of *in utero* tobacco exposure on DNA methylation in the blood of adult New Zealanders who were exposed to tobacco during development and explored the association between exposure during development with a high conduct problem score in childhood and adolescence.

Firstly, we assessed the effect of exposure to tobacco *in utero* on offspring DNA methylation, compared to non-exposed controls, without the interaction of CP score. No CpG sites reached an adjusted P value of significance (Table 2). However, the top nominally significant CpG sites were found in the genes *FRMD4A*, *MYO1G*, *WIPF3*, and *RTN1*. CpG sites in genes *MYO1G* and *FRMD4A* have been previously found to be differentially methylated in response to maternal smoking during pregnancy [40-42]. However, the CpG sites cg20745684 and cg01604380 within the genes *WIPF3* and *RTN1* respectively have not been implicated in any previous study.

Myosin 1G (*MYO1G*) and FERM Domain Containing 4A (*FRMD4A*) are more established biomarkers for *in utero* tobacco exposure [40-42]. However, these prior results come from the analysis of DNA methylation during childhood. Here, we show that methylation differences at these well-established biomarkers, in response to *in utero* tobacco exposure, are detectable in exposed individuals through to adulthood (age ~28 years), therefore our results expand on this current knowledge by demonstrating a potential for long-term stability of developmentally-induced methylation. We suggest that *MYO1G* and *FRMD4A* are specifically differentially methylated in response to maternal tobacco use during pregnancy, and that these methylation changes induced *in utero* appear to be stable into adulthood. Knowledge of the longevity of potentially developmentally-induced methylation marks may be important for understanding later-life disease risk, particularly given the association between *MYO1G* and immunity [43] and *FRMD4A* [44] with Alzheimer's disease.

Secondly, we assessed the interaction between *in utero* tobacco exposure and CP in exposed offspring on DNA methylation. Thus far, limited evidence has provided a molecular mechanism of the known association between maternal tobacco use

during pregnancy and the development of CP in exposed offspring. While no CpG sites displayed genome-wide significance under this interaction model, nominal significance was observed. Beta differences within the top 30 most nominally ($P < 0.01$) significant CpG sites were small, with the largest being 1.2%. The most differentially methylated CpG sites resided in the following genes: *FASTKD1*, *SLC10A7* and *LPIN1*.

Methylation at the CpG site in FAST Kinase domain 1 (*FASTKD1*) was elevated in those with high CP scores only in the exposed group (Figure 2). No methylation differences were found in those not exposed to maternal tobacco. Thus, this site in *FASTKD1* is a possible mediator of the known effect of maternal tobacco on CP. *FASTKD1* plays a role in the regulation of mitochondrial RNA [45, 46]. Single nucleotide variants within this gene have been associated with glaucoma [47], furthermore, this is evidence to suggest that children with vision impairment are more likely to be diagnosed with disorders such as ADHD than those that do not [48].

Solute Carrier Family 10 Member 7 (*SLC10A7*), Lipin 1 (*LIPIN1*) and Laminin gamma 3 (*LAMC3*) also contained top differentially methylated CpG sites. However, the interaction here is different to what was observed in *FASTKD1*. Differences in methylation are seen in the unexposed CP group. Thus, we hypothesise that these sites may be driven more so by unexposed high CP when compared to the exposed groups rather than the interaction of only exposed high CP. Furthermore, these genes do have functional relevance to the high CP phenotype. Single nucleotide variances in *LIPIN1* have been associated with neurofibrillary tangles which is a pathological protein aggregate found in Alzheimer's disease [49]. *LAMC3* has diverse roles in cell migration, apoptosis and adhesion, and variants within this gene have been found to contribute to cortical malformations [50-52]. It has been reported that individuals with these variants also have specific behavioural outcomes, e.g., impairments in endogenous attentional processes [51], which collectively suggests that these data may have biological relevance to the CP phenotype.

Therefore, while we detect biologically relevant nominally significant interactions between DNA methylation at individual CpG sites and high CP score in individuals exposed to tobacco *in utero*, further work is required to better characterise the precise mechanism of CP development. CP is a highly complex phenomenon that

encompasses a range of phenotypes [53], which will have a range of aetiologies. Hence the mechanism of CP development for non-exposed individuals with high CP is likely to be different to the individuals who were exposed to maternal tobacco smoke with the same phenotype. Our data identify potential epigenetic changes that could mediate the association between maternal smoking and conduct problems which persist into adulthood. These candidates require confirmation in larger independent studies.

Conclusion

Our findings here suggest that DNA methylation could be involved in the link between *in utero* tobacco exposure and conduct problems. While we were unable to identify genome wide differences in our cohort (N= 109), our results indicate that it would be beneficial to explore our nominal associations in a larger cohort. Further findings may help to elucidate the detrimental effect that *in utero* tobacco exposure has on the genome of exposed individuals, and suggest that disease associated DNA methylation which occurs early in the life course persists into adulthood.

Ethics approval and consent to participate.

All aspects of the study were approved by the Southern Health and Disability Ethics Committee, under application number CTB/04/11/234/AM10 “Collection of DNA in the Christchurch Health and Development Study”.

Funding

Seed grant - College of Science New Ideas Seed Grant to AJO.

CHDS was funded by the Health Research Council of New Zealand (Programme Grant 16/600)

CMRF provided the funding to write up the findings of this study.

Table 1 Cohort characteristics of the subset of individuals (n = 109) used to assess differential DNA methylation and *in utero* tobacco exposure, and their matched controls, all from the CHDS.

		<i>In utero</i> tobacco exposed group N= 49	Non-exposed control group N= 60
Sex			
Male		36	46
Female		13	14
Paternal socioeconomic status			
1		3	13
2		21	30
3		25	17
Adult tobacco smoking status			
Never smoker		26	52
Regular smoker		23	8
Conduct problem score (CP)			
Low CP (< 46)		26	41
High CP (> 53)		23	19

Table 2 Top differentially methylated CpG sites to *in utero* tobacco exposure in offspring. Beta values with P values, nominal and adjusted by the Benjamini and Hochberg method. Locations are relative to hg19 with gene names for overlapping genes or nearest 5'.

Illumina ID	Gene	Chromosome	Non exposed	Exposed	Difference	P value	Adjusted P value
cg25464840	<i>FRMD4A</i>	10	0.708	0.755	0.047	6.14E-07	0.247
cg15507334	<i>FRMD4A</i>	10	0.598	0.649	0.051	7.06E-07	0.247
cg04180046	<i>MYO1G</i>	7	0.513	0.587	0.074	1.45E-06	0.337
cg20745684	<i>WIPF3</i>	7	0.254	0.285	0.031	2.04E-06	0.356
cg01604380	<i>RTN1</i>	14	0.218	0.250	0.032	2.67E-06	0.374
cg22931725	<i>FMN2</i>	1	0.051	0.059	0.008	3.75E-06	0.391
cg06284231	<i>CLEC14A</i>	14	0.161	0.183	0.023	4.07E-06	0.391
cg02721176	<i>C10orf96</i>	10	0.300	0.363	0.064	4.95E-06	0.391
cg02841155	<i>SLC27A6</i>	5	0.257	0.304	0.047	5.37E-06	0.391
cg27339941		9	0.562	0.600	0.038	5.59E-06	0.391
cg01026094		20	0.284	0.322	0.038	6.36E-06	0.405
cg24601030	<i>DIXDC1</i>	11	0.756	0.797	0.041	8.04E-06	0.469
cg15433297	<i>PKHD1L1</i>	8	0.322	0.346	0.024	8.95E-06	0.482
cg05798339		3	0.344	0.359	0.015	1.13E-05	0.566
cg21771773		5	0.164	0.201	0.037	1.21E-05	0.566
cg15766464		5	0.477	0.505	0.029	1.37E-05	0.597
cg20595752	<i>TEAD3</i>	6	0.524	0.559	0.036	1.48E-05	0.610
cg06926300		10	0.159	0.168	0.008	1.64E-05	0.638
cg11813497	<i>FRMD4A</i>	10	0.767	0.817	0.050	1.87E-05	0.666
cg24149528		15	0.349	0.385	0.036	1.90E-05	0.666
cg10068883	<i>FAM166B</i>	9	0.595	0.637	0.043	2.10E-05	0.693
cg11157260		4	0.738	0.767	0.029	2.31E-05	0.693
cg13206397		16	0.891	0.881	-0.010	2.37E-05	0.693
cg16081285	<i>CSRNP3</i>	2	0.139	0.159	0.020	2.37E-05	0.693
cg19453818	<i>CAV2</i>	7	0.408	0.438	0.030	2.70E-05	0.726
cg15688339		5	0.384	0.446	0.062	2.83E-05	0.726
cg03770646		19	0.640	0.677	0.038	3.07E-05	0.726
cg06372850		2	0.222	0.265	0.043	3.07E-05	0.726
cg14644418	<i>FOXI2</i>	10	0.824	0.852	0.028	3.23E-05	0.726
cg25072920	<i>TCN1</i>	11	0.944	0.940	-0.004	3.39E-05	0.726

Table 3 Top differentially methylated CpG sites between *in utero* maternal tobacco exposure and the interaction with CP. Beta values with P values, nominal and adjusted by the Benjamini and Hochberg method. Locations relative to hg19 with gene names for overlapping genes or nearest 5' gene.

Illumina ID	Gene	Chromosome	<i>In utero</i> maternal tobacco exposed low CP	<i>In utero</i> maternal tobacco exposed high CP	Difference	P value	Adjusted P value
cg12163448	<i>FASTKD1</i>	2	0.142	0.155	0.013	1.01E-06	0.459
cg01210554		7	0.060	0.061	0.001	1.31E-06	0.459
cg13339919	<i>SLC10A7</i>	4	0.9457	0.9456	-0.0001	2.08E-06	0.486
cg21516989	<i>LPIN1</i>	2	0.946	0.947	0.001	6.89E-06	0.962
cg17343033		5	0.881	0.882	0.001	8.08E-06	0.962
cg01394525	<i>LAMC3</i>	9	0.910	0.915	0.005	8.82E-06	0.962
cg02809796	<i>PCGF3</i>	4	0.9185	0.9186	0.0001	9.62E-06	0.962
cg12361925	<i>FAM134A</i>	2	0.043	0.042	-0.001	1.37E-05	0.984
cg23048036	<i>CEP97</i>	3	0.808	0.796	-0.012	1.71E-05	0.984
cg05750962		18	0.082	0.083	0.001	2.80E-05	0.984
cg24835473	<i>CHCHD6</i>	3	0.931	0.929	-0.002	3.33E-05	0.984
cg23399286	<i>OC90</i>	8	0.8087	0.8088	0.0001	3.81E-05	0.984
cg16546489	<i>HSD17B1</i>	17	0.918	0.915	-0.003	3.84E-05	0.984
cg09692779		15	0.923	0.921	-0.003	3.88E-05	0.984
cg14496346		9	0.095	0.094	-0.001	4.02E-05	0.984
cg14420953		6	0.938	0.935	-0.003	4.10E-05	0.984
cg09125477	<i>C16orf91</i>	16	0.102	0.111	0.009	4.11E-05	0.984
cg11095011		6	0.936	0.935	-0.001	4.27E-05	0.984
cg24753210	<i>PPP1R14B</i>	11	0.068	0.066	-0.001	4.83E-05	0.984
cg25849390	<i>CCT6A</i>	7	0.884	0.880	-0.004	5.21E-05	0.984
cg13787134	<i>PHF2</i>	9	0.9391	0.9392	0.0001	5.46E-05	0.984
cg05858227		13	0.947	0.945	-0.002	5.58E-05	0.984
cg18168310		11	0.672	0.686	0.014	5.69E-05	0.984
cg06923651	<i>SPINK4</i>	9	0.437	0.438	0.001	6.06E-05	0.984
cg04807567	<i>MYO3B</i>	2	0.850	0.848	-0.002	6.25E-05	0.984
cg03243165		2	0.9393	0.9398	0.0005	6.45E-05	0.984
cg03492068		17	0.9100	0.9101	0.0001	7.06E-05	0.984
cg10671167	<i>CDK13</i>	7	0.083	0.084	0.001	7.47E-05	0.984
cg14778074	<i>GABRA2</i>	4	0.110	0.108	-0.002	7.60E-05	0.984
cg09482386	<i>CYB561</i>	17	0.941	0.940	-0.002	8.47E-05	0.984








Figure 1- The top four CpG sites differentially methylated due to *in utero* maternal tobacco exposure, these sites resided in genes *FRMD4A*, *MYO1G* and *WIPF3*. The log transformed normalised beta values of the non- exposed individuals are seen on the left, with the exposed *in utero* to tobacco individuals on the right.



402



403

404

405

406


407

Figure 2 caption-


The top four most significantly differentially methylated (nominal $P < 0.01$) CpG sites when *in utero* tobacco exposure was assessed with the interaction CP. Non-exposed individuals are plotted on the left of each plot, colour coded for either low CP (salmon) or high CP (cyan), with exposed individuals on the right. Lines from the non-exposed group to the exposed group represent the difference in average methylation between non-exposed and exposed with (salmon) and without (cyan) CP.

Supplementary Figure 1

A



B



470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487 References

488

- 489 1. Castles, A., et al., *Effects of smoking during pregnancy. Five meta-analyses*. Am J Prev Med, 1999. **16**(3): p. 208-15.
- 490 2. Blatt, K., et al., *Association of reported trimester-specific smoking cessation with fetal growth restriction*. Obstet Gynecol, 2015. **125**(6): p. 1452-9.
- 491 3. Baardman, M.E., et al., *Combined adverse effects of maternal smoking and high body mass index on heart development in offspring: evidence for interaction?* Heart, 2012. **98**(6): p. 474-479.
- 492 4. Hayatbakhsh, M.R., et al., *Maternal smoking during and after pregnancy and lung function in early adulthood: a prospective study*. Thorax, 2009. **64**(9): p. 810-814.
- 493 5. Beyer, D., H. Mitfessel, and A. Gillissen, *Maternal smoking promotes chronic obstructive lung disease in the offspring as adults*. European Journal of Medical Research, 2009. **14**(4): p. 27.
- 494 6. Kandall, S.R. and J. Gaines, *Maternal substance use and subsequent Sudden Infant Death Syndrome (SIDS) in offspring*. Neurotoxicology and Teratology, 1991. **13**(2): p. 235-240.
- 495 7. Andrews, A., et al., *Smoking prevalence trends: An analysis of smoking at pregnancy registration and at discharge from a midwife Lead Maternity Carer, 2008 to 2010*. New Zealand College of Midwives Journal, 2014. **49**.
- 496 8. Health, M.o., *Annual Update of Key Results 2017/18*, N.Z.H. Survey, Editor. 2018, In, Ministry of Health: Wellington, Ministry of Health.
- 497 9. Indredavik, M.S., et al., *Prenatal smoking exposure and psychiatric symptoms in adolescence*. Acta paediatrica (Oslo, Norway : 1992), 2007. **96**(3): p. 377-382.

- 509 10. Ekblad, M., et al., *Prenatal Smoking Exposure and the Risk of Psychiatric Morbidity Into*
510 *Young Adulthood*. Archives of General Psychiatry, 2010. **67**(8): p. 841-849.
- 511 11. Fergusson, D.M., L.J. Woodward, and L.J. Horwood, *Maternal Smoking During Pregnancy and*
512 *Psychiatric Adjustment in Late Adolescence*. Archives of General Psychiatry, 1998. **55**(8): p.
513 721-727.
- 514 12. Pratt, T.C., J.M. McGloin, and N.E. Fearn, *Maternal Cigarette Smoking During Pregnancy and*
515 *Criminal/Deviant Behavior: A Meta-Analysis*. International Journal of Offender Therapy and
516 Comparative Criminology, 2006. **50**(6): p. 672-690.
- 517 13. Brennan, P.A., E.R. Grekin, and S.A. Mednick, *Maternal smoking during pregnancy and adult*
518 *male criminal outcomes*. Arch Gen Psychiatry, 1999. **56**(3): p. 215-9.
- 519 14. Roza, S.J., et al., *Maternal smoking during pregnancy and child behaviour problems: the*
520 *Generation R Study*. International Journal of Epidemiology, 2008. **38**(3): p. 680-689.
- 521 15. Gaysina, D., et al., *Maternal smoking during pregnancy and offspring conduct problems:*
522 *evidence from 3 independent genetically sensitive research designs*. JAMA psychiatry, 2013.
523 **70**(9): p. 956-963.
- 524 16. Langley, K., et al., *Maternal smoking during pregnancy as an environmental risk factor for*
525 *attention deficit hyperactivity disorder behaviour. A review*. Minerva Pediatr, 2005. **57**(6): p.
526 359-71.
- 527 17. Kazdin, A.E., *Practitioner review: Psychosocial treatments for conduct disorder in children*.
528 Child Psychology & Psychiatry & Allied Disciplines, 1997. **38**(2): p. 161-178.
- 529 18. Zeilinger, S., et al., *Tobacco smoking leads to extensive genome-wide changes in DNA*
530 *methylation*. 2013. **8**(5): p. e63812.
- 531 19. Breton, C.V., et al., *Prenatal tobacco smoke exposure affects global and gene-specific DNA*
532 *methylation*. 2009. **180**(5): p. 462-467.
- 533 20. Ambatipudi, S., et al., *Tobacco smoking-associated genome-wide DNA methylation changes*
534 *in the EPIC study*. 2016. **8**(5): p. 599-618.
- 535 21. Gluckman, P.D., M.A. Hanson, and T. Buklijas, *A conceptual framework for the*
536 *developmental origins of health and disease*. Journal of Developmental Origins of Health and
537 Disease, 2009. **1**(1): p. 6-18.
- 538 22. Sengupta, S.M., et al., *Locus-specific DNA methylation changes and phenotypic variability in*
539 *children with attention-deficit hyperactivity disorder*. Psychiatry Research, 2017. **256**: p. 298-
540 304.
- 541 23. Joubert, B.R., et al., *450K epigenome-wide scan identifies differential DNA methylation in*
542 *newborns related to maternal smoking during pregnancy*. Environ Health Perspect, 2012.
543 **120**(10): p. 1425-31.
- 544 24. Joubert, B.R., et al., *DNA Methylation in Newborns and Maternal Smoking in Pregnancy:*
545 *Genome-wide Consortium Meta-analysis*. Am J Hum Genet, 2016. **98**(4): p. 680-96.
- 546 25. Joubert Bonnie, R., et al., *450K Epigenome-Wide Scan Identifies Differential DNA Methylation*
547 *in Newborns Related to Maternal Smoking during Pregnancy*. Environmental Health
548 Perspectives, 2012. **120**(10): p. 1425-1431.
- 549 26. Richmond, R.C., et al., *Prenatal exposure to maternal smoking and offspring DNA*
550 *methylation across the lifecourse: findings from the Avon Longitudinal Study of Parents and*
551 *Children (ALSPAC)*. Human Molecular Genetics, 2014. **24**(8): p. 2201-2217.
- 552 27. Richmond, R.C., et al., *Prenatal exposure to maternal smoking and offspring DNA*
553 *methylation across the lifecourse: findings from the Avon Longitudinal Study of Parents and*
554 *Children (ALSPAC)*. Human molecular genetics, 2015. **24**(8): p. 2201-2217.
- 555 28. Lee, K.W., Richmond, R., Hu, P., French, L., Shin, J., Bourdon, C., ... Pausova, Z. (2015).
556 Prenatal exposure to maternal cigarette smoking and DNA methylation: epigenome-wide
557 association in a discovery sample of adolescents and replication in an independent cohort at
558 birth through 17 years of age. Environmental health perspectives, 123(2), 193–199.
559 doi:10.1289/ehp.1408614.

- 560 29. Parmar, P., et al., *Association of maternal prenatal smoking GFI1-locus and cardio-metabolic*
561 *phenotypes in 18,212 adults*. EBioMedicine, 2018. **38**: p. 206-216.
- 562 30. Rutter M, T.J., Whitmore K, *Education, Health and Behaviour*. London: Longmans, 1970.
- 563 31. Conners, C.K., *Symptom patterns in hyperkinetic, neurotic, and normal children*. Child
564 Development, 1970. **41**(3): p. 667-682.
- 565 32. Conners, C.K., *A teacher rating scale for use in drug studies with children*. The American
566 Journal of Psychiatry, 1969. **126**(6): p. 884-888.
- 567 33. Fergusson, D.M., L.J. Horwood, and M. Lloyd, *Confirmatory factor models of attention deficit*
568 *and conduct disorder*. J Child Psychol Psychiatry, 1991. **32**(2): p. 257-74.
- 569 34. Fergusson, D.M., L.J. Horwood, and E.M. Ridder, *Show me the child at seven: the*
570 *consequences of conduct problems in childhood for psychosocial functioning in adulthood*. J
571 Child Psychol Psychiatry, 2005. **46**(8): p. 837-49.
- 572 35. Pidsley, R., et al., *Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for*
573 *whole-genome DNA methylation profiling*. Genome Biology, 2016. **17**(1): p. 208.
- 574 36. Triche, T.J., Jr, et al., *Low-level processing of Illumina Infinium DNA Methylation BeadArrays*.
575 Nucleic Acids Research, 2013. **41**(7): p. e90-e90.
- 576 37. Pearson, J.F., et al., *Increased risk of major depression by childhood abuse is not modified by*
577 *CNR1 genotype*. 2013(2): p. 224.
- 578 38. Lawrence, M., et al., *Software for computing and annotating genomic ranges*. PLoS
579 computational biology, 2013. **9**(8).
- 580 39. Wickham, H., *ggplot2: Elegant Graphics for Data Analysis*. 2016: Springer-Verlag New York.
- 581 40. Küpers, L.K., et al., *DNA methylation mediates the effect of maternal smoking during*
582 *pregnancy on birthweight of the offspring*. International Journal of Epidemiology, 2015.
583 **44**(4): p. 1224-1237.
- 584 41. Wiklund, P., et al., *DNA methylation links prenatal smoking exposure to later life health*
585 *outcomes in offspring*. Clinical Epigenetics, 2019. **11**(1): p. 97.
- 586 42. Vives-Usano, M., et al., *In utero and childhood exposure to tobacco smoke and multi-layer*
587 *molecular signatures in children*. BMC Medicine, 2020. **18**(1): p. 243.
- 588 43. Pierce, R.A., et al., *The HA-2 minor histocompatibility antigen is derived from a diallelic gene*
589 *encoding a novel human class I myosin protein*. J Immunol, 2001. **167**(6): p. 3223-30.
- 590 44. Lambert, J.C., et al., *Genome-wide haplotype association study identifies the FRMD4A gene*
591 *as a risk locus for Alzheimer's disease*. Molecular Psychiatry, 2013. **18**(4): p. 461-470.
- 592 45. Simarro, M., et al., *Fast kinase domain-containing protein 3 is a mitochondrial protein*
593 *essential for cellular respiration*. Biochemical and biophysical research communications,
594 2010. **401**(3): p. 440-446.
- 595 46. Boehm, E., et al., *FASTKD1 and FASTKD4 have opposite effects on expression of specific*
596 *mitochondrial RNAs, depending upon their endonuclease-like RAP domain*. Nucleic acids
597 research, 2017. **45**(10): p. 6135-6146.
- 598 47. Information, N.C.f.B. *NM_024622.6(FASTKD1):c.2230T>A (p.Tyr744Asn)*. [VCV000548952.1],
599 July,17th, 2018 24 Nov 2020].
- 600 48. DeCarlo, D.K., et al., *Prevalence of attention-deficit/hyperactivity disorder among children*
601 *with vision impairment*. Journal of American Association for Pediatric Ophthalmology and
602 Strabismus, 2014. **18**(1): p. 10-14.
- 603 49. Wang, H., et al., *Genome-wide interaction analysis of pathological hallmarks in Alzheimer's*
604 *disease*. Neurobiol Aging, 2020. **93**: p. 61-68.
- 605 50. Barak, T., et al., *Recessive LAMC3 mutations cause malformations of occipital cortical*
606 *development*. Nature genetics, 2011. **43**(6): p. 590-594.
- 607 51. Urgen, B.M., et al., *Homozygous LAMC3 mutation links to structural and functional changes*
608 *in visual attention networks*. Neurolmage, 2019. **190**: p. 242-253.
- 609 52. Barak, T., et al., *Recessive LAMC3 mutations cause malformations of occipital cortical*
610 *development*. Nature Genetics, 2011. **43**(6): p. 590-594.

611 53. Kazdin, A.E., *Conduct Disorders in Childhood and Adolescence*. 1995: SAGE Publications.

612